Key Highlights
- ImmunityBio shares declined 7.25% to close at $9.27 amid Friday’s volatile session.
- Phase 2/3 QUILT-3.032 trial demonstrated a 71% complete response rate in 100 bladder cancer patients.
- Complete responses lasted a median of 26.6 months, with some patients surpassing 53 months.
- Study participants who responded achieved 84% cystectomy-free survival at the three-year mark.
- Safety profile remained favorable with no Grade 4 or Grade 5 treatment-related adverse events reported.
Shares of ImmunityBio, Inc. (NASDAQ: IBRX) experienced a 7.25% decline on Friday, closing at $9.27 despite the biotechnology company unveiling substantial clinical trial progress. The stock shed $0.73 per share following a pronounced mid-morning selloff that extended throughout the trading session. Concurrently, the firm disclosed extended follow-up data demonstrating prolonged therapeutic benefits for patients battling aggressive forms of bladder cancer.
Stock Pressure Continues Despite Encouraging Trial Data Release
ImmunityBio witnessed sustained selling activity on October 16, even as the company disclosed favorable clinical trial outcomes. Trading volume intensified during a mid-morning downturn that propelled the stock’s losses deeper into negative territory. Nevertheless, the biotech firm published fresh evidence validating the efficacy of its ANKTIVA therapeutic approach for treating non-muscle invasive bladder cancer.
The organization revealed that The Journal of Urology had published extended data from its QUILT-3.032 clinical study, encompassing results from 100 participants diagnosed with BCG-unresponsive bladder cancer. Investigators assessed ANKTIVA when combined with Bacillus Calmette-Guérin in individuals presenting with carcinoma in situ alongside specific papillary tumor manifestations.
Trial outcomes documented a 71% complete response rate among study participants who received the dual-therapy regimen. Investigators also noted that the median duration of complete response reached 26.6 months, while certain patients experienced therapeutic benefits extending beyond 53 months. These data points offer additional confirmation of durable treatment efficacy in a patient population with severely restricted therapeutic alternatives.
Extended Follow-Up Reveals Durable Response Patterns
Trial analysis revealed that 63.8% of patients achieving complete responses sustained those outcomes for a minimum of 12 months. The data further demonstrated that 52.3% continued experiencing complete responses through the 24-month assessment, while 44.2% maintained therapeutic benefit through 36 months. Notably, more than half of the responders within the FDA-evaluated cohort preserved complete responses extending past the 45-month timepoint.
Additional analysis showed that 84% of responding patients avoided cystectomy surgery through the 36-month evaluation period. Disease-specific survival metrics reached an impressive 98.2% at the three-year mark, while progression-free survival measured 80.9%. Among the subset of patients who had never achieved remission with prior BCG treatment, investigators documented a 66% complete response rate with the combination approach.
The safety analysis throughout the prolonged observation period further strengthened the treatment’s clinical utility profile. Investigators documented Grade 3 treatment-related adverse events occurring in just 4% of trial participants, with a complete absence of Grade 4 or Grade 5 events. The majority of adverse reactions consisted of mild to moderate bladder-related symptoms directly associated with the administration method.
Regulatory Milestones Broaden Treatment Population
The FDA granted initial marketing authorization for ANKTIVA during 2024, creating a new therapeutic option for specific bladder cancer populations. This original approval encompassed adult patients diagnosed with BCG-unresponsive non-muscle invasive bladder cancer featuring carcinoma in situ. The regulatory agency subsequently broadened the approved treatment indication in October 2026, extending eligibility to encompass patients presenting with papillary-only disease manifestations.
ANKTIVA functions by stimulating natural killer cells alongside T cells, enabling the body’s immune defenses to identify and eliminate malignant cells. The therapeutic agent employs an interleukin-15 receptor agonist mechanism to enhance immune system function and promote sustained anti-tumor responses. ImmunityBio delivers the medication via direct intravesical instillation into the bladder together with BCG, rather than utilizing intravenous or subcutaneous injection routes.
Postponing definitive surgical intervention presents considerable clinical hazards for patients who may ultimately require bladder removal procedures. The official prescribing guidance recommends physicians reassess the necessity for cystectomy when patients demonstrate treatment failure following a second induction treatment cycle. Notwithstanding the promising clinical advancements announced Friday, ImmunityBio stock continued experiencing downward pressure, underscoring the disconnect between scientific progress and investor sentiment.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
